Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerPolicy UpdatesDurable Medical Equipment (DME)Aetna FES NMES Coverage & Prior Auth Policy Update…
    Ask Trek AI about this page

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    CurrentAetnaPolicy 0677

    Functional Electrical Stimulation (FES) and Neuromuscular Electrical Stimulation (NMES)

    Customize your policy alerts

    Sign up for Aetna Policy 0677 alerts

    Get alerted when Policy 0677 changes without checking for updates manually.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    Coverage and medical necessity criteria for FES and NMES as durable medical equipment (DME), including specific device indications, contraindications, training requirements, and devices considered experimental or unproven; applies to Aetna members under the referenced clinical policy.

    Policy Summary
    PayerAetna
    PolicyFunctional Electrical Stimulation (FES) and Neuromuscular Electrical Stimulation (NMES)
    Policy CodePolicy 0677
    Change TypeNo material change
    Effective DateFeb 6, 2004
    Last ReviewJul 30, 2026
    Next Review DateJul 23, 2026
    Key ActionProvide documentation showing completion of at least 32 physical therapy sessions over a 3-month training program and evidence that selection criteria are met when requesting coverage for Parastep I FES ambulation devices.
    SourceLink
    POLICY UPDATE CHANGES

    No material clinical or coverage changes in this revision.

    32 sessionsParastep training requirement
    <=2 hrs/dayMax NMES daily use
    51%Remede ≥50% AHI reduction
    151RCTs for phrenic PNS
    NumerousDevices listed as experimental/unproven

    Coverage Criteria for FES and NMES

    FES for ambulation - Initial therapy

    Covered when ALL of the following are met

    FES ambulation (Parastep I) criteria: 1) Member has intact lower motor units (L1 and below) (both muscle and peripheral nerve); 2) Member has joint stability to bear weight on upper and lower extremities and has balance and control to maintain an upright posture independently; 3) Member demonstrated brisk muscle contraction to neuromuscular electrical stimulation and has sensory perception of electrical stimulation sufficient for muscle contraction; 4) Member has the cognitive ability to use such devices for walking and is highly motivated to use the device long term; 5) Member can transfer independently and stand for at least 3 minutes; 6) Member possesses hand and finger function to manipulate the controls; 7) Member is at least 6 months post recovery of spinal cord injury and restorative surgery; 8) Member does not have hip and knee degenerative disease and has no history of long bone fracture secondary to osteoporosis; 9) Member has successfully completed a training program consisting of at least 32 physical therapy sessions with the device over a 3-month period; 10) Member has none of the contraindications listed in the policy (see Contraindications group).32 PT sessions / 3 months

    All items must be met for coverage.

    Contraindications

    Not eligible if ANY of the following contraindications are present

    Policy Summary
    PayerAetna
    PolicyFunctional Electrical Stimulation (FES) and Neuromuscular Electrical Stimulation (NMES)
    Policy CodePolicy 0677
    Change TypeNo material change
    Effective DateFeb 6, 2004
    Last ReviewJul 30, 2026
    Next Review DateJul 23, 2026
    Key ActionProvide documentation showing completion of at least 32 physical therapy sessions over a 3-month training program and evidence that selection criteria are met when requesting coverage for Parastep I FES ambulation devices.
    SourceLink
    On This Page
    Coverage Criteria for FES and NMESCoding — CPT, HCPCS, ICD-10 ReferencesProvider Actions, Prior Authorization & DocumentationMedical Necessity Considerations & Decision NodesRental, Purchase and Replacement RulesReplacement and ConsumablesRequired Documentation to Support CoverageNot Covered / Experimental / Investigational UsesDefinitions and Device DescriptionsBackground and Clinical Evidence SummaryPolicy Revision History
    FES ambulation contraindications: 1) Cardiac pacemaker; 2) Severe scoliosis or severe osteoporosis; 3) Skin disease or cancer at the area of stimulation; 4) Irreversible contracture; 5) Autonomic dysreflexia.

    Presence of any one contraindication excludes FES for walking (Parastep I).

    NMES for disuse atrophy

    Covered when ALL of the following are met

    NMES disuse atrophy criteria: 1) Nerve supply to the target muscle is intact; and 2) Member has any of the following non-neurological reasons for disuse atrophy: contractures due to burn scarring; major knee surgery (e.g., total knee replacement) with failure to respond to physical therapy; previous casting or splinting of a limb with failure to respond to physical therapy; or recent hip replacement surgery prior to initiation of physical therapy (NMES may be used until PT begins).

    If nerve supply is not intact or condition not listed, coverage is not supported. NMES >2 hours/day is considered not medically necessary.

    Form-fitting conductive garment

    Covered when ALL of the following are met

    Form-fitting conductive garment: 1) The garment is approved for marketing by the FDA; and 2) It is prescribed by a physician for delivery of NMES that is medically necessary; and 3) Any of the following apply: the member cannot manage stimulation with conventional electrodes because of a large area or large number of sites or frequency of stimulation required; the member has a skin problem or other condition precluding conventional electrodes; the member requires stimulation beneath a cast to treat disuse atrophy when nerve supply is intact; or the member has a medical need for rehabilitation strengthening where nerve supply is intact.

    HCPCS E0731 applies; garments are considered experimental/unproven for other indications.

    Diaphragmatic/phrenic pacing - Indications

    Covered when ALL of the following criteria are met for each indication group

    Diaphragmatic pacing for ventilatory function in SCI: 1) High quadriplegia at or above C-3; 2) Viable phrenic nerves; 3) Adequate diaphragm and lung function; 4) Diaphragmatic pacing will allow the individual to breathe without mechanical ventilator assistance for at least four continuous hours per day.>=4 hours/day

    Stable, non-acute SCI members.

    Diaphragmatic pacing for central alveolar hypoventilation: 1) Age 18 years or older; 2) Intact phrenic nerve function; 3) Demonstrable diaphragm movement with stimulation.
    Diaphragmatic pacing for amyotrophic lateral sclerosis (ALS): 1) Age 21 years or older; 2) Experiencing chronic hypoventilation; 3) Intact phrenic nerve function; 4) Diaphragm movement with stimulation; 5) Diaphragmatic pacing is used as an alternative to mechanical ventilation.

    Device replacement

    Replacement coverage

    Device replacement: Replacement of an FES or diaphragmatic/phrenic stimulation system is medically necessary when the original device met medical necessity criteria, is no longer under warranty, and cannot be repaired.

    Provide operative/device history and documentation of warranty/repair attempts and reason for replacement (e.g., battery depletion).

    Covered when selection criteria are met

    Covered when ALL of the following are met (general framing present in document):

    General coverage conditional: Specific CPT, HCPCS and ICD-10 codes listed in the policy are covered only when the selection/medical necessity criteria for the specific device and indication are met and documented; coverage of listed codes is contingent on meeting those device-specific criteria.

    Refer to individual device selection/medical necessity criteria for the applicable code.

    Not medically necessary / not covered categories

    Not covered for CPB-listed indications:

    Not covered HCPCS/CPT/ICD categories: Multiple HCPCS, CPT and ICD-10 codes and device categories are explicitly listed as not covered for the indications in the clinical policy bulletin (examples include HCPCS A4544, E0743, E0770, A4560; HCPCS L8720/L8721 for Walkasins; and a range of ICD-10 diagnoses identified in the policy).

    Full code lists and excluded indications are provided in the coding section of the policy.

    Indication-specific evidence summaries

    Evidence summaries and situational coverage context present the following distinct indication groups and evidentiary conclusions

    NMES after ligament/knee surgery: NMES has been shown in cited studies to prevent muscle atrophy associated with knee immobilization, enable earlier ambulation, reduce analgesic use, and shorten hospital stay; overall evidence quality is limited and volitional exercise may be more effective in many situations.

    References include Arvidsson (1986); Lake (1992); Gotlin et al (1994); Snyder-Mackler et al (1995); Bax et al (2005).

    Implanted sacral anterior root stimulation for supra-sacral SCI: Implanted systems with posterior rhizotomy demonstrated improved bladder emptying (void >200 mL, residual <50 mL) and reduced catheter use in selected patients when reflexes and cystometry criteria are met.

    Selection based on presence of reflexes and cystometric phasic detrusor pressure criteria.

    Transurethral electrical bladder stimulation (TEBS): Randomized and controlled trials did not demonstrate durable benefit for TEBS; TEBS has limited clinical utility in cited trials.

    Boone et al (1992) randomized sham-controlled trial showed no benefit.

    Cerebral palsy: NMES may show improvements in ROM and motor scores in small or uncontrolled studies for selected children with mild CP; overall evidence insufficient for routine coverage.

    Evidence limited to small/uncontrolled studies.

    Bell's palsy: No evidence supports routine use of electrical stimulation in acute idiopathic Bell's palsy; limited/low-quality evidence may suggest benefit in chronic cases only.
    Foot drop (FES devices): FES devices (WalkAide, NESS L300, implanted peroneal stimulators) show mixed evidence: some trials demonstrate orthotic benefit and equivalence to AFOs, while others show exercise or AFO may be superior; long-term therapeutic effects and superiority remain unproven.

    Further high-quality comparative studies are needed.

    Evidence-based patient groups

    Coverage considerations informed by trial populations and outcomes

    TOMAC — populations studied: Trials enrolled patients with moderate-to-severe RLS, often medication-refractory; primary outcomes included IRLS and CGI-I/PGI-I responder rates with demonstrated short-term symptom reductions in randomized trials and extensions.

    RESTFUL and other randomized trials cited; TOMAC use typically limited to studied populations.

    Walkasins — populations studied: Trials enrolled patients with peripheral neuropathy, impaired plantar sensation, high fall risk (FGA < 23), and ability to sense tactile stimuli above the ankle; outcomes included FGA, gait speed, TUG, and falls with improvements reported up to 26 weeks but evidence limited by small/uncontrolled designs.

    Walk2Wellness trials reported improvements at 10 and 26 weeks.

    Walkasins and lower limb sensory prostheses

    Summary coverage stance from evidence presented in this section

    Evidence-based coverage considerations for Walkasins: There is insufficient high-quality evidence to support routine coverage of lower limb sensory prostheses (e.g., Walkasins) for long-term gait improvement; further comparative studies with larger samples and control groups are needed.

    Based on narrative review and pilot/extension study limitations.

    NMES adjunctive uses (emerging evidence)

    Ongoing and emerging NMES indications under study

    NMES adjunctive therapy research: NMES is being evaluated as an adjunct to core stability exercise for non-specific low back pain, as an adjunct to multi-modality balance interventions for fall prevention in older adults, for preservation of muscle in dialysis patients, and for treatment of sarcopenic obesity; current data are from protocols, early recruitment, or systematic reviews showing potential but heterogeneous evidence.

    Trials are ongoing or in protocol stages; evidence not yet sufficient for routine coverage.

    The policy identifies numerous devices and indications as experimental, investigational, or unproven. Examples explicitly listed include FES of the upper extremities (e.g., NESS H200/Handmaster) and a wide range of other applications for FES/NMES such as Bell’s palsy, cerebral palsy, COPD, congestive heart failure, erectile dysfunction, general muscle strengthening in healthy individuals, and improvement of ambulatory function in progressive diseases (see enumerated list in the scope). These device/indication groupings are treated as lacking established effectiveness in the evidence base and therefore are not supported for routine coverage.

    The policy also lists multiple specific devices and device classes considered unproven, for example: AxioBionics wearable NMES for hemiplegia, Cala Trio (wrist-worn peripheral nerve stimulation), EMG-triggered NMES (Care ETS), implanted FES for gait after stroke, PoNS (trans‑lingual neurostimulation), TOMAC, Walkasins, wearable geko NMES devices, and a variety of FES exercise systems (MyoCycle, RT-series, SpectraSTIM). Many of these technologies are described as having insufficient or mixed evidence to establish long‑term functional benefit or to justify routine DME coverage.

    Where the document details indications judged investigational, it notes either small/uncontrolled studies, absence of durable functional outcomes, or inconsistent trial results supporting that determination. Providers should therefore plan prior authorization or coverage requests for these devices on the expectation that a strong evidence package or enrollment in an approved clinical trial will be required to justify use.

    The policy includes explicit lists of CPT/HCPCS and ICD‑10 codes that are not covered for the indications listed in this clinical policy bulletin (CPB). Representative HCPCS codes identified as not covered for CPB indications include A4544, E0743, L8720, L8721, E0770, E0745, among others. These codes map to external lower extremity nerve stimulators (e.g., TOMAC), external lower extremity sensory prostheses (Walkasins), and miscellaneous functional electrical stimulator systems not otherwise specified.

    The ICD‑10 section similarly enumerates diagnosis codes that are either excluded or require that selection criteria be met for coverage; examples include diagnosis ranges for malignant neoplasms (C00.0‑C95.92), multiple sclerosis (G35), Bell’s palsy (G51.0), restless legs syndrome (G25.81), and various gait/mobility and neuromuscular diagnoses. The policy states that some ICD‑10 codes are covered only if the policy’s selection/medical necessity criteria are met and that other listed ICD‑10 codes are not covered for CPB‑listed indications.

    Providers should note that billing of the listed HCPCS/CPT codes for indications explicitly designated as not covered in the CPB will be considered not covered / not medically necessary and may trigger claim denials unless the patient and indication align with the policy’s specified selection criteria.

    Multiple background reviews and systematic reviews cited in the policy conclude there is insufficient evidence to demonstrate sustained, long‑term functional effectiveness of FES as a rehabilitative intervention after stroke. The document notes that while FES has been used to address joint contracture, maintain range of motion, and facilitate voluntary motor control, the available data do not robustly support improvements in long‑term functional outcomes or independence in activities of daily living for stroke survivors.

    The policy references guideline reviews and Cochrane‑style assessments that found either no recommendation for routine post‑stroke FES or that evidence is inadequate to inform clinical use. These sources emphasize the need for higher‑quality trials addressing dose, timing, and device type before routine coverage for stroke rehabilitation can be justified.

    Accordingly, practitioners seeking coverage for FES in post‑stroke rehabilitation should anticipate that the policy regards long‑term benefit as unproven and that documentation must address the evidence gaps identified in the literature if a coverage exception is sought.

    Transurethral electrical bladder stimulation (TEBS) is described in the policy background as having failed to demonstrate durable benefit in multiple studies. Earlier positive reports were not replicated by more recent trials, and investigators characterized TEBS as time‑consuming, labor‑intensive, and of limited urodynamic benefit. Because of these limitations some programs no longer accept new TEBS patients.

    Given this evidence summary, TEBS is presented as a therapy with limited clinical utility and not supported for routine adoption in the treatment of neurogenic bladder dysfunction in the contexts reviewed.

    The policy notes that for many wearable and external chronic stimulation technologies the long‑term effects and durability of benefit are unknown. Narrative reviews of lower‑limb sensory prostheses and other wearable devices report mixed short‑term results, small heterogeneous study populations, limited follow‑up, and difficulty separating device effects from concurrent rehabilitative interventions.

    These evidence gaps mean that the long‑term clinical effectiveness and safety profile of chronic external electrical stimulation devices remain uncertain, and routine long‑term coverage is not supported by the current literature summarized in this policy.

    An UpToDate review cited in the policy (Badr, 2015) did not list phrenic nerve stimulation among therapeutic options for central sleep apnea, indicating that at the time of that review phrenic nerve stimulation had limited inclusion in commonly used clinical guidance.

    The document contrasts that guideline absence with later device‑specific evidence and FDA approval (see Remede System discussion), noting constrained guideline uptake despite emerging randomized and nonrandomized data.

    The Remede System (implantable phrenic nerve stimulator) has specific contraindications and device limitations noted in its evidence summary and FDA documentation. The policy states the device should not be used in patients with an active infection and should not be implanted in patients who are known to require MRI, given device and lead characteristics.

    These device‑specific constraints should be considered in patient selection and in pre‑implant screening and documentation for prior authorization or surgical planning.

    Randomized double‑blind cross‑over trials of sacral neuromodulation (SNS) for chronic constipation reported no statistically significant difference between active and sham stimulation and a high sham responder rate (30–60%). These findings, together with reported complication rates, undermine the strength of evidence supporting SNS for constipation and make it difficult to recommend as a standard treatment within constipation algorithms.

    The policy therefore reflects caution about routine implantation of SNS for constipation and highlights the need for clear test‑stimulation response and durable benefit before permanent implantation is justified.

    A cited UpToDate review on lower extremity peripheral nerve syndromes does not include neuromuscular stimulation as a therapeutic option, suggesting limited or nonstandard endorsement of NMES for many peripheral nerve disorders in guidance literature.

    Additionally, several clinical trials excluded patients with implanted electronic medical devices (e.g., pacemakers, defibrillators, deep brain stimulators) and those who had prior neurosurgical ET interventions, which constrains generalizability of study findings to populations with such devices or prior procedures.

    Evidence for the Cala system (wrist‑worn TAPS/Cala Trio) is described as inconsistent and insufficient to support implementation as standard of care for essential tremor. Reviews and RCTs show some short‑term reductions in tremor severity and ADL improvements, but confidence in sustained benefit beyond a few months is low and direct comparisons with other ET treatments are lacking.

    The policy highlights limitations including small trial sizes, open‑label designs, and uncertainty about durability of effect, indicating further investigation is needed before routine coverage can be supported.

    Multiple device studies summarized in the policy explicitly excluded participants with implanted electronic medical devices (for example pacemakers, implantable cardioverter‑defibrillators, or deep brain stimulators) and those who had received certain surgical therapies for essential tremor. These exclusions limit applicability of trial results to patients with such prior devices or procedures.

    Providers should therefore be aware that study populations frequently omitted these subgroups and that evidence of safety and efficacy in those patients is commonly absent.

    Wearable NMES products such as the geko T‑3 and W‑3 are FDA‑cleared devices designed to stimulate the common peroneal nerve to increase calf muscle pump activity, and the policy describes their mechanism and intended indications. However, the policy also states there is a lack of evidence regarding their clinical value (i.e., insufficient high‑quality data demonstrating clinical outcomes such as wound healing or VTE prevention).

    Consequently, routine coverage for these wearable NMES devices is limited by the evidence gap and decisions may require additional supporting documentation or demonstration of medical necessity.

    The TOMAC (Tonic Motor Activation) trial evidence summarized in the policy is primarily specific to medication‑refractory moderate‑to‑severe restless legs syndrome. The RESTFUL randomized trial and extensions enrolled patients refractory to at least one medication; the policy notes that effectiveness in medication‑naïve or mild RLS populations has not been established.

    Guideline sources cited in the document do not consistently mention TOMAC as a therapy, and the policy underscores the need for additional studies to evaluate effectiveness in broader RLS populations.

    The document explicitly states that there are no published data for TOMAC use in patients with mild or previously untreated RLS; existing studies enrolled moderate‑to‑severe, medication‑refractory patients. As a result, application of TOMAC outside the studied, refractory population remains unproven.

    Coverage decisions for TOMAC should therefore consider whether the patient matches the trial populations (medication‑refractory, moderate‑to‑severe RLS) before supporting routine home use.

    Lower limb sensory prostheses such as Walkasins are reviewed in the policy narrative; although some studies report short‑term improvements in gait and balance measures, the overall literature is limited by small sample sizes, heterogeneous populations, combined intervention protocols, and short follow‑up. The policy concludes there is insufficient evidence to support routine coverage of lower limb sensory prostheses for sustained gait improvement.

    The document recommends further comparative studies with larger samples and controlled designs before these devices can be recommended for routine DME coverage.

    The policy states a clear utilization threshold for external NMES: use exceeding 2 hours per day is considered not medically necessary. Literature protocols and the policy itself recommend no more than 2 hours of NMES within any 24‑hour period, and exceeding that daily limit may lead to claim denial.

    Providers should document prescribed daily regimen and ensure prescribed NMES use aligns with this ≤2 hours/day threshold when requesting coverage or supplying devices.

    The policy clarifies that billing use of HCPCS/CPT codes listed as not covered for the CPB indications will be treated as not covered / not medically necessary. Examples called out in the code lists include peroneal stimulator/system codes and other HCPCS items (e.g., E0770, E0743, A4560) that are explicitly associated with non‑covered CPB indications.

    When submitting claims, providers must ensure the patient diagnosis and documented medical necessity match the policy’s covered selection criteria; otherwise billing with the listed codes for excluded indications may be denied.

    Across stroke rehabilitation literature summarized in the policy, systematic reviews and guideline assessments conclude that evidence is insufficient to support FES as an effective rehabilitative modality for stroke patients with respect to long‑term functional outcomes. Cochrane and guideline reviews emphasize the need for higher‑quality trials to define optimal device parameters, dose, and timing.

    Consequently, routine coverage of FES for stroke rehabilitation is not supported by the current evidence base presented in the policy and requests should be supported by robust trial‑like evidence if exceptions are considered.

    The policy cites evidence concluding that electrotherapy is not advised for management of acute idiopathic Bell’s palsy. Reviews found no advantage of electrostimulation over facial exercises or other conservative measures in the acute setting; limited and low‑quality data suggest possible benefit in chronic cases but do not support routine use in initial management.

    Providers treating Bell’s palsy should therefore follow established conservative and medical therapies and recognize that electrotherapy lacks guideline endorsement for acute idiopathic Bell’s palsy.

    Within the chunks referenced there are no explicit additional 'not medically necessary' determinations beyond the specific exclusions and thresholds already stated (for example, the NMES >2 hours/day rule and code‑based not‑covered lists). The document primarily provides background evidence summaries and code lists rather than standalone additional NMN rulings in these excerpts.

    Coding — CPT, HCPCS, ICD-10 References

    Covered CPT Codes (implantation-related)CPTCovered
    63655Laminectomy for implantation of neurostimulator electrodes, plate/paddle, epidural.
    63685Insertion or replacement of spinal neurostimulator pulse generator or receiver, direct or inductive coupling.
    64555Percutaneous implantation of neurostimulator electrodes; peripheral nerve (excludes sacral nerve).
    64575Incision for implantation of neurostimulator electrodes; peripheral nerve (excludes sacral nerve).
    64585Revision or removal of peripheral neurostimulator electrodes.
    64590Insertion or replacement of peripheral or gastric neurostimulator pulse generator or receiver, direct or inductive coupling.
    64595Revision or removal of peripheral or gastric neurostimulator pulse generator or receiver.
    Covered HCPCS and supply codesHCPCSCovered
    A4556Electrodes (e.g., apnea monitor), per pair.
    A4557Lead wires (e.g., apnea monitor), per pair.
    A4558Conductive gel or paste, for use with electrical device (e.g., TENS, NMES), per oz.
    A4595Electrical stimulator supplies, 2 lead, per month, (e.g. TENS, NMES).
    E0731Form-fitting conductive garment for delivery of TENS or NMES (with conductive fibers separated from the patient's skin by layers of fabric).
    E0745Neuromuscular stimulator, electronic shock unit.
    E0764Functional neuromuscular stimulator, transcutaneous stimulation of muscles of ambulation with computer control, used for walking by spinal cord injured, entire system, after completion of training program.
    E0770Functional electrical stimulator, transcutaneous stimulation of nerve and / or muscle groups, any type, complete system, not otherwise specified.
    L8680Implantable neurostimulator electrode, each.
    L8681Patient programmer (external) for use with implantable programmable neurostimulator pulse generator.
    1–10 of 17
    1/2
    HCPCS codes not covered for indications listedHCPCSNot Covered
    E0762Transcutaneous electrical joint stimulation device system, includes all accessories.
    ICD-10 codes (examples listed; covered and not-covered ranges also present)ICD-10
    S12.000A - S12.691SFracture of vertebral column
    S12.9xxA - S12.9xxSFracture of vertebral column (other ranges listed)
    S22.000A - S22.089SFracture of thoracic spine
    S32.000A - S32.2xxSFracture of lumbar spine/pelvis
    G12.20 - G12.9Motor neuron disease
    G35Multiple sclerosis
    G51.0Bell's palsy (facial palsy)
    M17.0 - M17.9Osteoarthritis of knee
    M21.371 - M21.379Foot drop (acquired)
    Covered/related CPT CodesCPTCovered
    64580Open implantation of neurostimulator electrode array; neuromuscular
    63190Laminectomy with rhizotomy; more than two segments
    63185Laminectomy with rhizotomy; one or two segments
    Diaphragmatic/Phrenic Pacing CPT CodesCPTCovered
    33277Insertion of phrenic nerve stimulator transvenous sensing lead
    33278Removal of phrenic nerve stimulator, including pulse generator and lead(s)
    33279Transvenous stimulation or sensing lead(s) only
    33280Pulse generator only
    33281Repositioning of phrenic nerve stimulator transvenous lead(s)
    33287Removal and replacement of phrenic nerve stimulator; pulse generator
    33288Transvenous stimulation or sensing lead(s)
    64580Open implantation of neurostimulator electrode array; neuromuscular
    93150Therapy activation of implanted phrenic nerve stimulator system
    93151Interrogation and programming of implanted phrenic nerve stimulator system
    1–10 of 11
    1/2
    Covered HCPCS (when selection criteria met)HCPCSCovered
    E0745Neuromuscular stimulator, electronic shock unit
    E0731Form fitting conductive garment for delivery of TENS or NMES
    A4556Electrodes (e.g., apnea monitor), per pair
    A4557Lead wires (e.g., apnea monitor), per pair
    A4595Electrical stimulator supplies, 2 lead, per month (e.g., TENS, NMES)
    L8680Implantable neurostimulator electrode, each
    L8681Patient programmer (external) for use with implantable programmable neurostimulator pulse generator
    L8685Implantable neurostimulator pulse generator, single array, rechargeable, includes extension
    L8686Implantable neurostimulator pulse generator, single array, non-rechargeable, includes extension
    L8687Implantable neurostimulator pulse generator, dual array, rechargeable, includes extension
    1–10 of 12
    1/2
    HCPCS codes listed as not covered for CPB indicationsHCPCSNot Covered
    A4544Electrode for external lower extremity nerve stimulator for restless legs syndrome (TOMAC)
    E0743External lower extremity nerve stimulator for restless legs syndrome
    L8720External lower extremity sensory prosthesis (Walkasins), per leg
    L8721Receptor sole for use with L8720, replacement, each
    A4560Neuromuscular electrical stimulator (NMES), disposable, replacement only
    E0770Functional electrical stimulator, transcutaneous stimulation of nerve and/or muscle groups, any type, complete system, not otherwise specified
    E0734External upper limb tremor stimulator of the peripheral nerves of the wrist
    A4542Supplies and accessories for external upper limb tremor stimulator of the peripheral nerves of the wrist
    ICD-10 codes (examples) — covered or conditionalICD-10
    G71.8Other specified myopathies
    M62.50Muscle wasting and atrophy, not elsewhere classified
    M62.84Sarcopenia
    G35Multiple sclerosis
    G51.0Bell's palsy (facial palsy)
    I69.351Hemiplegia and hemiparesis following cerebral infarction
    G82.51Quadriplegia C1-C4 complete
    Z94.2Lung transplant status
    Remede system / central sleep apnea codesmixedCovered
    0424TInsertion or replacement of neurostimulator system for treatment of central sleep apnea
    0427TInsertion or replacement of neurostimulator system for treatment of central sleep apnea (series 0424T-0427T referenced)
    C1823Generator, neurostimulator (implantable), non-rechargeable, with transvenous sensing and stimulation leads
    Example NMES device names mentionedmixed
    Empi 300 PVExample of NMES device (device name, not a billing code)
    NexWaveExample of NMES device (device name, not a billing code)
    R2i muscle stimulatorExample of NMES device (device name, not a billing code)
    Named NMES/FES/TENS devices in backgroundmixed
    Care ETSEMG-triggered NMES device (device name)
    VitalStim TherapyNMES system proposed for dysphagia treatment
    Guardian dysphagia dual chamberDevice proposed for pharyngeal muscle re-education
    Empi PhoenixCombination NMES and TENS device
    QB1 powered muscle stimulatorCombination NMES and TENS device
    RS-4i sequential stimulatorCombination/interferential + muscle stimulator
    Kneehab XP / KneeHAB IIGarment-integrated NMES device for knee rehabilitation
    Implantable phrenic nerve stimulation devicemixed
    Remede SystemImplantable phrenic nerve stimulation system approved by FDA for adult moderate-to-severe CSA
    Diagnosis codes referenced in studiesICD-10
    G25.0Essential tremor
    No codes in this excerptmixed
    No codes listed
    FES training and NMES daily use — training and daily use limits
    FES training requirementAt least 32 physical therapy sessions with the device over a 3-month training program (Parastep I).
    NMES daily use limitNo more than 2 hours of NMES treatment within a 24‑hour period; >2 hours/day is not medically necessary.
    Form‑fitting garment noteWhen NMES delivered via garment, criteria for NMES and garment must both be met (garment FDA‑marketed and physician‑prescribed).
    Parastep training sessions — at least 32 sessions
    Minimum Parastep training sessionsAt least 32 training sessions are required for the Parastep I System (training over a 3‑month period).
    Program basisParastep training requirement is adapted from FDA labeling and clinical studies describing 32 sessions.
    Training purposeTraining enables standing and short‑distance ambulation; completion is a coverage criterion for FES ambulation.
    Phasic detrusor pressure rise on cystometry — numeric thresholds
    Female thresholdPhasic detrusor pressure rise >= 35 mm H2O on cystometry (female).
    Male thresholdPhasic detrusor pressure rise >= 50 cm H2O on cystometry (male).
    Reflex requirementPresence of 3 of 4 non‑vesical sacral segment reflexes required in selection criteria (ankle jerks, bulbo‑cavernous reflex, anal skin reflex, reflex erection).
    Apnea-Hypopnea Index (AHI) — trial eligibility threshold
    AHI eligibility threshold (PNS RCT)Apnea‑Hypopnea Index (AHI) >= 20 events per hour on polysomnography for trial eligibility in PNS randomized trial.
    Stability requirementPatients were required to be medically stable for at least 30 days prior to enrollment (trial context).
    Age requirement (trial)Adults aged >=18 years were enrolled in the referenced RCT (informational).
    AHI reduction — ≥50% reduction at 6 months
    Primary effectiveness threshold>= 50% reduction in AHI from baseline at 6 months (primary endpoint in phrenic nerve stimulation RCT).
    Remede System performanceIn FDA evaluation, 51% of patients had >=50% AHI reduction at 6 months with active Remede System; control reduction ~11%.
    Assessment methodAHI measured by full‑night PSG assessed in a core laboratory (trial standard).
    FEV1 for COPD trial enrollment — <50% predicted
    FEV1 threshold for COPD NMES trialsFEV1 < 50% predicted used as enrollment criterion in an RCT of NMES for severe COPD (informational).
    Symptom requirementSubjects had incapacitating breathlessness (MRC dyspnea scale >=4) in the cited trial.
    Trial durationActive NMES was applied daily over a 6‑week period in the referenced RCT.
    Claims requirement — ≥2 claims with ICD-10-CM G25.0 separated ≥7 days within last 3 years
    Claims verification requirementAt least 2 medical claims with ICD‑10‑CM code G25.0 (essential tremor) separated by >=7 days within the last 3 years required for study enrollment/documentation in TAPS device context.
    Screening documentationScreening questionnaire confirming ET symptoms and baseline ADL survey required alongside physician confirmation of diagnosis.
    Physician confirmationPhysician confirmation of neurologic diagnosis included on prescription form for device in cited studies.
    FGA threshold — FGA score < 23 indicates high fall risk
    FGA fall‑risk thresholdFunctional Gait Assessment (FGA) score < 23 indicates high fall risk and was an enrollment criterion in Walkasins studies.
    Outcome measuresFGA, gait speed, Timed Up and Go (TUG) and 4‑Stage Balance Test used as clinical outcomes in Walkasins trials.
    Sensation requirementAbility to sense tactile stimuli above the ankle required for Walkasins candidacy in cited trials.
    TOMAC daily use limit — Maximum 120 minutes/day (30-min sessions)
    TOMAC daily session limitTypical session duration 30 minutes; patients may use up to a maximum of 120 minutes per day (e.g., four 30‑minute sessions).
    Indication contextUsed for medication‑refractory moderate‑to‑severe RLS in RESTFUL trial participants.
    FDA statusDevice received FDA marketing approval in April 2023 (contextual).

    Provider Actions, Prior Authorization & Documentation

    Prior Authorization

    DME prior authorization for FES/NMES

    When billing for listed FES/NMES DME items (for example HCPCS E0764, E0745, E0731, A4595), prior authorization is implied — coverage is contingent on meeting the policy’s selection/medical necessity criteria for the specific device and indication.

    • Covered HCPCS/ CPT/ ICD codes are conditional on meeting device-specific selection criteria.
    • Provide documentation that the patient meets the clinical criteria referenced in the policy when requesting authorization.
    Prior Authorization

    Prior authorization for implantable and external NMES/FES

    Certain implantable and external neuromuscular stimulator devices (examples include HCPCS E0745 and implantable neurostimulator codes L8685–L8689) are covered only if selection criteria are met — prior authorization is implied when those criteria apply.

    • Include device model and evidence the patient meets the policy’s selection criteria with the PA request.
    • Implantable device claims (L8685–L8689) require documentation of indication and candidacy.
    Prior Authorization

    Prior authorization — implanted diaphragmatic pacing

    For diaphragmatic/diaphragm pacing implants, if prior authorization is requested include documentation of laparoscopic diaphragm motor‑point mapping and pre‑implant respiratory function (e.g., FVC) and evidence of candidacy per the policy’s selection criteria.

    • Document motor point mapping and intra‑muscular electrode stimulation testing performed during implantation.
    • Provide baseline respiratory measures and justification that pacing would allow ≥4 continuous hours off mechanical ventilation when applicable.
    Prior Authorization

    Implanted sacral root stimulator prior authorization

    Implanted sacral anterior root stimulators (e.g., Vocare/Finetech‑Brindley) are supported in selected supra‑sacral SCI patients; prior authorization requests should include evidence of reflex testing and cystometry consistent with implant candidacy.

    • Provide documentation that 3 of 4 non‑vesical sacral segment reflexes are present.
    • Include cystometry showing phasic detrusor pressure rise (≥35 mm H2O female; ≥50 cm H2O male) and trial response data.
    Note

    Prior authorization not specified in this section

    The policy text contains no explicit payer prior‑authorization code requirements for many background device discussions; when PA processes are used, the document supplies evidentiary context rather than administrative code triggers.

    • Absence of explicit PA codes in these sections means PA expectations derive from covered‑when‑selection‑criteria‑met language elsewhere.
    • Use the device‑specific selection criteria and codes elsewhere in the policy to determine PA needs.
    Note

    Clinical trial eligibility noted

    Clinical trial eligibility criteria (e.g., AHI ≥20 events/hour for phrenic nerve stimulation trials) are described for research enrollment but do not substitute for payer prior authorization; include trial‑level evidence only as supporting documentation when applicable.

    • Trial enrollment criteria (AHI ≥20, medically stable ≥30 days) are informational — provide diagnostic testing and prior therapy documentation for PA.
    • Do not assume trial criteria equal PA criteria unless payer explicitly adopts them.
    Prior Authorization

    Prior authorization for implantable phrenic nerve stimulators

    For implantable phrenic nerve stimulators (Remede System), prior authorization requests should document diagnosis of moderate‑to‑severe central sleep apnea, prior standard therapies attempted, and device candidacy (sleep testing distinguishing central vs obstructive events).

    • Include PSG/AHI results and prior trials of mask‑based therapy, oxygen, or pharmacotherapy.
    • Note the Remede System contraindications (active infection, MRI dependence) when assessing candidacy.
    Prior Authorization

    Prior authorization expectations for SNS

    Given mixed or unfavorable evidence for sacral neuromodulation (SNS) in chronic constipation and reported complication rates, prior authorization should require documentation of refractory symptoms, prior conservative therapies tried, and explicit discussion of uncertain benefit.

    • Provide bowel diaries, standardized constipation scores, record of prior therapies attempted, and test‑stimulation response if available.
    • Highlight known device‑related adverse events and prior trial outcomes in the PA submission.
    Prior Authorization

    Prior authorization for chronic device use (wrist‑worn PNS)

    When requesting long‑term/home use coverage for wrist‑worn peripheral nerve stimulation devices (e.g., Cala/TAPS), consider prior authorization supported by baseline and follow‑up objective clinician‑ and device‑recorded measures demonstrating benefit.

    • Submit baseline TETRAS and BF‑ADL scores and device accelerometer usage logs showing improvements over time.
    • Document prescribed regimen (e.g., twice‑daily use), duration of home trial, and clinician assessments.
    Prior Authorization

    Prior authorization expectation (Cala/TAPS)

    Studies of Cala/TAPS included prescription processes and collection of device logs and patient‑reported outcomes; PA requests for similar devices should supply diagnosis confirmation, device usage logs, and measured benefit as documented in trials.

    • Provide physician confirmation of neurologic diagnosis on the prescription form and screening questionnaire results.
    • Attach device‑recorded tremor power and ADL changes from the monitored trial period.
    Prior Authorization

    Prior authorization likely required for FDA‑cleared wearable devices

    Coverage decisions for FDA‑cleared wearable NMES or FES technologies (e.g., geko, MyoCycle Home) may require prior authorization with documentation of the indication, device model/FDA status, and supporting clinical evidence aligned to the policy criteria.

    • Include device model, FDA clearance information, indication being treated, and objective baseline and follow‑up functional or metabolic measures.
    • For disposable wearable devices (e.g., geko), note intended use period and any device log data collected.
    Note
    Prior Authorization

    TOMAC prior authorization evidence

    For TOMAC (Tonic Motor Activation) prior authorization include the RESTFUL randomized trial and extension study results (CGI‑I responder rates, IRLS score changes) and documentation that the patient is medication‑refractory when applicable.

    • Attach RESTFUL trial outcomes (45% vs 16% CGI‑I responder at 4 weeks) and extension study durability data to support the PA.
    • Document prior medication trials and refractory status in the medical record.
    Prior Authorization

    Device use should align with trial inclusion criteria

    Prior authorization requests for devices studied in trials should demonstrate that the patient matches trial inclusion criteria (for example, TOMAC: medication‑refractory moderate‑to‑severe RLS; Walkasins: impaired plantar sensation plus FGA <23) and include relevant outcome measures and prior treatment history.

    • Provide baseline functional measures (e.g., IRLS for RLS or FGA for Walkasins) and documentation of prior therapies attempted.
    • When device use deviates from trial populations, include justification and supporting evidence.
    Prior Authorization

    Prior authorization may be required for Walkasins

    Because evidence for lower‑limb sensory prostheses (e.g., Walkasins) is limited, prior authorization may be required; include documentation of peripheral neuropathy with impaired plantar sensation, FGA <23, ability to perceive tactile cues above the ankle, and baseline/follow‑up gait outcomes.

    • Submit FGA, gait speed, TUG and documentation of impaired plantar sensation and ability to sense device cues.
    • If long‑term benefit is asserted, provide trial data or study participation details to support ongoing coverage.
    Step Therapy

    Step therapy for diaphragmatic/phrenic pacing

    Diaphragmatic/phrenic pacing is reserved for refractory respiratory indications after failure of other therapies (mask‑based therapies, oxygen, pharmacotherapy); document prior conservative therapy attempts and rationale for implantable pacing.

    • Show prior use and intolerance/failure of mask‑based therapies or other standard treatments.
    • Provide objective respiratory testing and evidence supporting diaphragmatic pacing candidacy.
    Step Therapy

    Conservative therapy prior to FES

    For foot‑drop FES, payers may expect a trial of standard conservative therapy (AFO or exercise) before approving FES devices because some trials show comparable or superior effects with these conservative options.

    • Document prior use of an AFO or supervised exercise therapy and clinical response.
    • Include rationale if FES is sought without prior conservative therapy.
    Step Therapy

    Comparative device sequencing (FES vs AFO)

    Comparative trials often evaluate FES versus ankle‑foot orthoses (AFO); when sequencing devices, document prior orthotic trials and patient preference or demonstrated orthotic limitations to support progression to FES.

    • Provide results of prior AFO use, device preference assessments, and functional test results (10‑m walk, 6‑min walk).
    • If FES is requested after AFO, include objective measures showing inadequate function with orthosis.
    Step Therapy

    Test stimulation before permanent implant

    Clinical trial designs for implantable neuromodulation commonly required test stimulation and demonstration of benefit before permanent implantation; include test‑stimulation records and documented response when seeking coverage for permanent implants.

    • Attach test‑stimulation monitoring results, symptom diaries, and documented clinical response prior to permanent implant request.
    • Provide records of prior conservative management and why permanent implantation is indicated.
    Step Therapy

    Step: prior PT trial (TLNS/PoNS)

    For TLNS/PoNS adjunctive use, document a prior plateau on conventional physical therapy and provide objective baseline and follow‑up balance assessments (e.g., SOT, DGI) to support coverage.

    • Include documentation of a documented plateau in PT and pre/post SOT or DGI scores.
    • Show the course and duration of prior PT and objective evidence of persistent deficit.
    Documentation Required

    Training completion and prior device necessity

    Document completion of at least 32 physical therapy sessions over a 3‑month Parastep training program and evidence that the original device met medical necessity when requesting FES for ambulation or device replacement.

    • Provide PT session logs showing ≥32 sessions over 3 months.
    • For replacements, include warranty/repair attempts and that the original device met policy criteria.
    Documentation Required

    Form‑fitting garment documentation

    When a form‑fitting conductive garment (HCPCS E0731) is used to deliver NMES, include a physician prescription stating the garment is FDA‑marketed and justification why conventional electrodes are impractical or contraindicated.

    • Attach documentation that the garment is FDA‑approved for marketing.
    • Provide clinical justification (large stimulation area, skin condition, stimulation under cast) for garment use.
    Documentation Required

    Medical necessity documentation for billed codes

    When billing HCPCS/CPT codes for stimulators, electrodes, leads, or implantable components that are conditioned on selection criteria, include supporting medical necessity documentation demonstrating the patient meets the policy’s criteria for the specific code and device.

    • Correlate each billed HCPCS/CPT code with the policy criterion satisfied in the medical record.
    • Include objective outcome measures and prior therapy history relevant to the coded device.
    Documentation Required

    Device prescription and procedural documentation (DPS)

    Series of diaphragm pacing implantations reported laparoscopic diaphragm motor‑point mapping and intra‑muscular electrode implantation with perioperative assessments; include operative notes and motor‑point mapping/stimulation testing in records when submitting implant or PA requests.

    • Submit operative reports documenting laparoscopic motor‑point mapping and intra‑muscular electrode placement.
    • Include perioperative respiratory measures (e.g., FVC) and stimulation testing results.
    Documentation Required

    Implant selection documentation (sacral stimulators)

    For implanted sacral anterior root stimulation, document the presence of 3 of 4 non‑vesical sacral reflexes and cystometry demonstrating the phasic detrusor pressure rise thresholds specified in the policy.

    • Provide cystometry results showing phasic detrusor pressure rise (≥35 mm H2O female; ≥50 cm H2O male).
    • Document presence of ankle jerks, bulbocavernosus reflex, anal skin reflex, or reflex erection as applicable.
    Documentation Required

    Clinical outcome documentation

    Include objective clinical outcome measures (e.g., 10‑m walk, 6‑min walk, gait speed, FGA, Stroke Impact Scale) and device‑recorded metrics when submitting evidence of benefit for FES/NMES devices.

    • Attach baseline and follow‑up gait/mobility measures and device logs demonstrating functional change.
    • Report adverse events and therapy adherence as part of follow‑up documentation.
    Documentation Required

    Provide operative/device history and replacement justification

    When requesting replacement of an implanted device (e.g., Remede generator), provide operative/device history and justification for replacement such as documented battery depletion or device end‑of‑life evidence (mean Remede battery life ~4.2 years reported).

    • Include prior implant operative report, device interrogation showing battery status, and reason for replacement.
    • Cite observed mean battery life data if relevant to timing of replacement.
    Documentation Required

    Documentation of test stimulation response and prior conservative management

    For permanent implantable neuromodulation devices (e.g., SNS for constipation), provide test‑stimulation records, symptom diaries, validated symptom scores, and documentation of prior conservative management as prerequisites for coverage review.

    • Attach test‑stimulation response documentation and bowel diaries or standardized constipation/incontinence scores.
    • Detail prior therapies attempted and duration of conservative management.
    Documentation Required

    Include device usage logs and objective tremor outcomes

    To support continued home‑use coverage of wrist‑worn tremor devices, include device usage logs, on‑board accelerometry tremor power metrics, clinician‑rated TETRAS and patient BF‑ADL scores at baseline and follow‑up demonstrating benefit.

    • Provide device session logs, objective accelerometer tremor power pre/post metrics, and clinician/patient rated outcome scales over the home‑use period.
    • Report adverse events (e.g., skin irritation) and adherence rates.
    Documentation Required

    Use of ICD‑10‑CM G25.0 and diagnostic documentation

    When using the ET diagnosis code (ICD‑10‑CM G25.0) as part of enrollment or coverage logic, ensure at least two diagnostic claims or equivalent diagnostic documentation are present and that the physician confirmed the neurologic diagnosis on the prescription form, as done in cited trials.

    • Provide ≥2 medical claims with ICD‑10‑CM G25.0 separated by ≥7 days within the last 3 years or equivalent documentation.
    • Include physician confirmation of diagnosis on prescription and screening questionnaire results.
    Denial Risk

    FES ambulation selection criteria not met — denial risk

    Failure to meet all Parastep (FES ambulation) selection criteria (intact lower motor units, ability to transfer/stand, completion of ≥32 PT sessions over 3 months, etc.) will render FES for walking not medically necessary and is a basis for denial.

    • Confirm intact lower motor units (L1 and below), ability to transfer independently and stand ≥3 minutes, hand function to operate controls.
    • Provide PT training records showing completion of ≥32 sessions over 3 months.
    Denial Risk

    Excessive NMES daily use (>2 hours) — denial risk

    Use of NMES for more than 2 hours within a 24‑hour period is considered not medically necessary per the policy; claims documenting excessive daily use risk denial.

    • Ensure prescribed and documented daily NMES use does not exceed 2 hours in any 24‑hour period.
    • If longer use is proposed, provide explicit supporting clinical justification and trial evidence.
    Denial Risk

    Not‑covered HCPCS triggers — denial risk

    Billing with HCPCS codes that the policy lists as 'not covered for indications listed in the CPB' (examples include A4544, E0743, L8720/L8721, A4560) may trigger claim denials; ensure codes align with covered indications and documented selection criteria.

    • Verify the HCPCS billed matches a covered indication and that selection criteria supporting coverage are documented.
    • Avoid using HCPCS flagged as not covered for the CPB indications unless coverage criteria are explicitly met.
    Denial Risk

    Not‑covered peroneal stimulator/system codes (e.g., E0770) — denial risk

    Use of peroneal stimulator/system HCPCS codes explicitly listed as not covered for CPB indications (for example E0770) may trigger denials; submit detailed clinical justification and evidence if using these codes for off‑label or non‑CPB indications.

    • If E0770 or similar codes are submitted, include documentation that the indication falls within a covered exception and meets policy criteria.
    • Provide trial data or device‑specific evidence to support medical necessity for non‑covered code use.
    Denial Risk

    TEBS limited utility — denial risk

    Transurethral electrical bladder stimulation (TEBS) has limited clinical benefit and programs have ceased accepting new patients; requests for TEBS as effective therapy are at risk for denial due to time‑intensive procedure and lack of durable benefit in trials.

    • Provide rigorous objective evidence if asserting benefit for TEBS in a specific patient; otherwise, expect nonsupport for coverage.
    • Highlight that TEBS trials demonstrated limited urodynamic and functional improvement.
    Note

    No explicit administrative prior authorization triggers present

    There is no explicit administrative prior authorization or coding denial trigger in many background sections — reviewers should rely on the policy’s coverage statements (covered when selection criteria are met) and the listed code tables to determine PA needs.

    • Use the policy’s covered‑when‑selection‑criteria language and specific code lists to decide when PA is required.
    • Background evidence summaries alone do not constitute administrative PA rules.
    Denial Risk

    Remede System contraindications — denial risk

    Claims for the Remede System submitted for patients with active infection or those requiring MRI are contraindicated and may be denied; verify contraindications before authorization and document absence of active infection and MRI dependence.

    • Document absence of active infection and whether the patient requires MRI before approving Remede device implantation.
    • Include PSG/AHI data and prior therapy attempts to support device candidacy.
    Denial Risk

    Adverse events and limited efficacy (SNS) — denial risk

    High device‑related adverse event rates and inconsistent efficacy for sacral neuromodulation in constipation are documented; lack of demonstrated benefit or complications may lead to coverage denial for SNS in chronic constipation.

    • Provide long‑term follow‑up data, complication history, and objective symptom measures to support a PA for SNS.
    • Be aware that RCTs for constipation have not consistently shown benefit and reported substantial AEs.
    Denial Risk

    Evidence limitations may affect coverage — denial risk

    Single‑session, open‑label, or small uncontrolled studies without durability data may not support long‑term coverage decisions; absence of randomized or durable evidence is a common basis for denial of chronic home‑use claims.

    • Attach randomized controlled trial data or longer‑term controlled follow‑up when available.
    • If only single‑session or open‑label evidence exists, expect additional documentation requests or denial for long‑term coverage.
    Denial Risk

    Data insufficiency may affect coverage decisions

    Missing or poor‑quality device measurement data (e.g., incomplete accelerometry, voluntary survey nonresponse) in real‑world datasets can prevent demonstration of effectiveness and may result in denial or requests for additional documentation.

    • Ensure device‑recorded data are complete and linked to clinician assessments when submitted for PA or continued coverage.
    • Provide objective pre/post device metrics rather than solely voluntary surveys.
    Denial Risk

    Evidence insufficiency for wearable NMES — denial risk

    Lack of robust clinical evidence for wearable NMES devices (e.g., geko T‑3/W‑3) may trigger coverage denial or requests for supporting documentation demonstrating clinical value for the specific indication.

    • When seeking coverage for wearable NMES, include device‑specific FDA clearance details and clinical evidence supporting the intended use.
    • Be prepared to supply device logs, outcome measures, and rationale when evidence is limited.
    Denial Risk

    Insufficient group‑level efficacy in intermittent claudication trial — denial risk

    A multicenter RCT of NMES for intermittent claudication failed to show statistically significant improvement in absolute walking distance across the whole cohort at 3 months; lack of group‑level efficacy can be cited to deny broad coverage for IC populations.

    • Document why the patient may differ from trial populations (e.g., mild claudication subgroup) if asserting benefit.
    • Consider supervised exercise therapy (SET) evidence and prior SET attempts in the record.
    Denial Risk

    Evidence limited outside studied populations — denial risk

    Lack of evidence for populations outside those studied (for example, TOMAC data largely in medication‑refractory moderate‑to‑severe RLS) may lead to denial when patients do not match trial populations; ensure alignment with trial inclusion or provide robust justification.

    • If treating medication‑naïve or mild RLS patients with TOMAC, provide explicit supportive evidence as trials focused on refractory moderate‑to‑severe cases.
    • For devices studied in specific cohorts, include matching baseline severity and prior therapy history in PA documentation.

    Medical Necessity Considerations & Decision Nodes

    Rental, Purchase and Replacement Rules

    Device / SystemPurchase vs Rental Rule
    FES devices for walking (e.g., Parastep I)
    Purchase — replacement allowed if original device met medical necessity, is no longer under warranty, and cannot be repaired
    Diaphragmatic/phrenic stimulation systems
    Purchase — replacement permitted when original device met medical necessity and is no longer under warranty and cannot be repaired
    Device / SystemPurchase vs Rental Rule
    External NMES units (HCPCS examples: E0745, E0731, A4556-A4595)
    Purchase vs rental not specified in excerpt
    Implantable neurostimulators and components (HCPCS examples: L8680-L8689)
    Purchase vs rental not specified in excerpt
    Device / SystemPurchase vs Rental Rule
    NESS H200 / Handmaster (upper‑extremity surface neuroprosthesis)
    Purchase
    Device / SystemPurchase vs Rental Rule
    Vocare / Finetech‑Brindley (sacral anterior root stimulator with posterior rhizotomy)
    Purchase (implantable system) — intended as an implanted device rather than rented DME
    Device / SystemPurchase vs Rental Rule
    WalkAide (peroneal nerve stimulator)
    Purchase
    NESS L300 / BioNESS L300 (peroneal/foot‑drop stimulators)
    Purchase
    Device / SystemPurchase vs Rental Rule
    Various foot‑drop and wearable neuromodulation devices discussed in these sections
    No rental vs purchase rules specified in these chunks
    Device / SystemPurchase vs Rental Rule
    Remede phrenic nerve stimulator (transvenous phrenic nerve stimulation)
    Purchase — implantable system; replacements documented for battery depletion
    Device / SystemPurchase vs Rental Rule
    Remede System (implantable PNS system)
    Purchase — implantable device pathway; generator replacement described for battery depletion (mean battery life ~4.2 years)
    Device / SystemPurchase vs Rental Rule
    Garment‑integrated NMES (e.g., KneeHAB II)
    Rental or purchase (both rental and purchase noted)
    Portable NMES units / combination NMES-TENS devices (e.g., Empi Phoenix, QB1, Kneehab XP)
    Rental or purchase (both rental and purchase noted)
    Device / SystemPurchase vs Rental Rule
    Wearable multi‑channel NMES and surface FES devices (multi‑channel wearable systems)
    Purchase
    Device / SystemPurchase vs Rental Rule
    Cala Trio / TAPS (wrist‑worn peripheral nerve stimulator)
    Purchase — prescribed for home use; device is FDA‑cleared and described as prescribed home device
    Device / SystemPurchase vs Rental Rule
    geko T‑3 and geko W‑3 (wearable NMES OnPulse devices)
    Capped rental — disposable after use and replaced as required (device applied and discarded after use)
    Device / SystemPurchase vs Rental Rule
    geko (disposable adhesive wearable NMES)
    Purchase for single‑use consumable application (device removed/discarded after use)
    MyoCycle Home (FES cycle device)
    Purchase — FDA‑cleared home‑use therapeutic device
    Device / SystemPurchase vs Rental Rule
    TOMAC (Tonic Motor Activation) system — wearable peroneal nerve stimulation
    No explicit rental vs purchase rules provided in excerpt — described as wearable system for ongoing home use
    Walkasins lower‑limb sensory prosthesis
    No explicit rental vs purchase rules provided in excerpt — described as wearable system for ongoing home use
    Device / SystemPurchase vs Rental Rule
    Walkasins and similar lower‑limb wearable neuromodulation/sensory prostheses
    Purchase (policy notes devices intended for ongoing home use; purchase rule indicated in rental/purchase inventory)

    Replacement and Consumables

    FES for walking; diaphragmatic/phrenic stimulation systems — replacement not specified
    Replacement not specified for FES/walking and DPSPolicy states replacement of FES for walking or diaphragmatic/phrenic stimulation systems is medically necessary if original device met criteria and is no longer under warranty and cannot be repaired; no specific replacement interval is specified.
    Replacement contingent on warranty/repairReplacement eligibility requires demonstration that original device met medical necessity and is not repairable and out of warranty.
    Diaphragmatic/phrenic systemsSame replacement logic applies to diaphragmatic/phrenic pacing systems per policy statements.
    Consumable supplies and replacement components — documentation and coverage context
    Consumables and suppliesElectrodes, lead wires, conductive gel/paste, and electrical stimulator supplies (HCPCS A4556‑A4595) are listed and imply replacement/consumable coverage as billed; explicit intervals not provided in excerpt.
    Documentation contextWhen billing HCPCS/CPT for stimulators and supplies, documentation must support that selection/medical necessity criteria are met for the specific device/code billed.
    Garment componentsForm‑fitting conductive garment (E0731) and associated accessories are covered when FDA‑marketed and criteria are met; replacement rules not detailed.
    Implanted diaphragmatic pacing systems — replacement considerations
    Implanted DPS replacementPolicy provides no explicit replacement interval for implanted diaphragmatic pacing systems; replacements are considered when device no longer under warranty and cannot be repaired.
    Operative history documentationSeries describing DPS implantation reference laparoscopic motor‑point mapping and electrode implantation; documentation of prior implant and reason for replacement is relevant.
    Battery/longevity contextObservational reports document device longevity and replacements, but explicit payer intervals not specified in policy excerpts.
    Remede phrenic nerve stimulator battery life — mean ~4.2 years
    Remede battery life (mean)Mean reported battery life for the Remede implantable phrenic nerve stimulator is approximately 4.2 years (mean 4.2 ± 0.2 years).
    Replacement as neededRemede pulse generator replacements have been performed for battery depletion; replacement timing guided by battery end‑of‑life.
    Clinical follow‑upLong‑term follow‑up reported stable efficacy and stable lead positions over 4 years in replacement series.
    Remede System implantable pulse generator — mean reported battery life ~4.2 years (replacement as needed)
    Remede IPG battery lifeMean reported battery life for the Remede System implantable pulse generator is approximately 4.2 years; replacement performed as needed for battery depletion.
    Replacement procedure timeMean replacement procedure time reported ~25 minutes in a consecutive replacement series.
    Safety/efficacy over timeClinical reports indicated sustained therapy efficacy and no major complications over 4 years in replacement cohorts.
    geko devices — replaced after each use period as indicated (disposable)
    geko device disposabilitygeko T‑3 and W‑3 devices are adhesive, wearable NMES units that are removed and discarded after use; a new device is applied as required (single‑use/disposable replacement).
    Usage duration capabilityGeko devices can deliver NMES for up to 24 hours per day depending on device and indication; devices are replaced after each use period.
    IndicationsIndications include increased local blood circulation, edema reduction, prevention of venous thrombosis, and support of wound/tissue healing in venous insufficiency/ischemia.
    Not specified — placeholder block for replacement rules not detailed in inventory
    No specific replacement rulePolicy excerpts do not specify additional replacement intervals or rules beyond those listed for particular devices (see device‑specific entries).
    Replacement evidence requirementFor replacements, provide operative/device history and justification (e.g., battery depletion, out of warranty, non‑repairable).
    Consult full policyRefer to full policy or payer billing guidance for any device‑specific replacement coding or interval policies not present in these excerpts.

    Required Documentation to Support Coverage

    Documentation Required

    Supply documentation of criteria, training completion, and device warranty/repair history

    Provide clinical documentation showing the patient meets device‑specific medical necessity criteria, evidence of training completion (e.g., ≥32 PT sessions for Parastep), and device warranty/repair attempts for replacement requests.

    • Attach PT training logs, device repair history, and statements regarding warranty status for replacement claims.
    • Ensure clinical notes explicitly map patient findings to the policy's selection criteria.
    Documentation Required

    Physician prescription and justification required for form‑fitting garments

    When a form‑fitting conductive garment is used, include a physician prescription and justification describing why conventional electrodes are impractical and documentation that the garment is FDA‑marketed (HCPCS E0731).

    • Prescriber statement explaining large stimulation area, skin issues, or cast application that preclude conventional electrodes.
    • Evidence of FDA marketing/clearance for the specific garment model.
    Billing Rule

    Support all stimulator/lead/implant claims with medical necessity documentation

    When billing covered HCPCS/CPT for stimulators, electrodes, leads, or implantable components, include medical necessity documentation that demonstrates the patient meets the policy's selection criteria for the specific code/device billed.

    • Tie each billed code to the policy's listed covered codes and include clinical evidence that selection criteria are satisfied.
    • Exclude billing codes that the policy lists as not covered for the indication.
    Documentation Required

    Include laparoscopic motor point mapping and stimulation testing records for DPS

    DPS implantation series referenced laparoscopic motor point mapping and intra‑muscular electrode implantation with perioperative assessments; include operative notes and stimulation testing records as applicable when seeking authorization.

    • Attach laparoscopic motor point mapping reports, intra‑operative stimulation findings, and perioperative respiratory assessments.
    • Include post‑operative conditioning/stimulation plans when available.
    Documentation Required

    Document reflexes and cystometry thresholds for implant selection

    For implanted sacral anterior root stimulation, document the presence of 3 of 4 non‑vesical sacral segment reflexes and cystometry showing phasic detrusor pressure thresholds (≥35 mm H2O female; ≥50 cm H2O male) to support implant candidacy.

    • Provide cystometry reports and reflex testing documentation used to determine intact efferent supply to the bladder.
    • Include trial stimulation/voiding trial results if performed.
    Documentation Required

    Submit trial‑used objective outcome measures to support device benefit

    Include objective functional outcome measures used in trials (e.g., 10‑m walk, 6‑minute walk, GaitRite FAP, mEFAP, Berg Balance Scale, TUG) when submitting medical necessity evidence for FES or wearable gait devices.

    • Provide baseline and follow‑up scores for relevant functional tests to demonstrate treatment effect.
    • If device is for balance/gait, include validated scales such as FGA or TUG as applicable.
    Documentation Required

    Provide device history and battery depletion evidence for replacements

    Provide operative/device history and justification for replacement claims (for example, evidence of battery depletion or device end‑of‑life such as mean Remede battery life ~4.2 years) to support implantable device replacement coverage.

    • Attach prior implant operative reports, device interrogation showing battery status, and clinical rationale for replacement.
    • Cite documented mean battery life where relevant (Remede ~4.2 years) to justify timing of replacement.
    Documentation Required

    Provide test‑stimulation response and prior conservative management records for implants

    When requesting coverage for permanent implantable neuromodulation, include documentation of test stimulation response and evidence of prior conservative management per trial designs and device selection practices.

    • Attach test stimulation logs, symptom diaries, validated symptom scores, and a record of prior therapies and outcomes.
    • Document any complications or reasons for proceeding to permanent implantation.
    Documentation Required

    Include device usage logs and objective tremor metrics to support ongoing home‑use coverage

    For continued home‑use coverage of tremor‑targeting devices, include device usage logs and objective outcome measures (e.g., TETRAS, BF‑ADL, wrist accelerometer tremor power) to document benefit over time.

    • Submit device‑recorded accelerometry pre/post session metrics, clinician TETRAS scores, and patient BF‑ADL reports.
    • Provide periodic follow‑up data showing sustained functional improvement to justify ongoing coverage.
    Documentation Required

    Provide pre/post accelerometry and ADL assessments when using device logs in coverage decisions

    If device logs or objective tremor measurements are used for coverage decisions, include pre/post postural hold accelerometry and ADL assessments as done in trials and post‑market studies.

    • Provide examples of pre/post session accelerometry snapshots and associated ADL score changes.
    • Include adherence data (frequency/duration of sessions) from device logs.
    Note
    Note
    Note
    Note
    Note

    Not Covered / Experimental / Investigational Uses

    The policy explicitly classifies a set of FES exercise devices — including the FES Power Trainer, ERGYS/REGYS systems, MyoCycle, RT series (RT200/RT300/RT600), and SpectraSTIM — as exercise equipment. These stationary FES exercise systems are considered excluded by most benefit plans and are treated as non‑covered exercise equipment rather than medically necessary DME.

    The policy contains an explicit list of HCPCS, CPT and ICD‑10 codes and device categories that are not covered for the CPB‑listed indications. Representative HCPCS entries flagged as not covered include A4544, E0743, E0770, E0745 and codes for Walkasins (L8720/L8721); corresponding ICD‑10 diagnosis ranges (e.g., C00.0–C95.92) and neurologic codes such as G35 are detailed in the code tables and described as not covered when used for the listed indications.

    TEBS is described in the policy as not producing beneficial effects in multiple studies; investigators reported limited urodynamic benefit and practical limitations (time‑consuming, labor intensive), and some programs stopped accepting new patients, supporting a not‑covered stance for TEBS as effective therapy.

    The policy cites randomized studies of threshold electrical stimulation (TES) and transcutaneous electrical therapies in children with spastic diplegic cerebral palsy that showed no significant objective motor or ambulatory benefit. Based on these trial data, TES for spastic diplegic CP is listed among indications lacking demonstrated clinical benefit.

    Wearable NMES devices (e.g., geko T‑3 and W‑3) are discussed as FDA‑cleared technologies but the policy emphasizes that clinical benefit has not been demonstrated for many indications. The document states a lack of evidence regarding their clinical value and identifies this as a reason to consider such devices not covered for some uses.

    For postoperative recovery indications, the policy highlights systematic review findings that evidence for NMES is of low‑to‑very‑low certainty across many outcomes. Heterogeneous controls and low certainty of evidence limit confidence that NMES provides consistent postoperative benefit, supporting not‑covered or investigational designations for many recovery uses.

    Definitions and Device Descriptions

    Form-fitting conductive garment — definition and HCPCS cross-reference
    DefinitionForm‑fitting conductive garment: a garment approved for marketing by the FDA designed to deliver NMES when conventional electrodes are impractical (HCPCS E0731).
    Coverage conditionCovered only when garment is FDA‑marketed, physician‑prescribed for medically necessary NMES, and criteria for garment use are met (large area, skin problems, beneath cast, or rehabilitation strengthening).
    HCPCS cross‑referenceHCPCS code: E0731 applies to form‑fitting conductive garments for delivery of TENS or NMES.
    Functional Electrical Stimulation (FES) for ambulation — definition and example (Parastep I)
    DefinitionFunctional Electrical Stimulation (FES) for ambulation: transcutaneous, computer‑controlled stimulation (e.g., Parastep I, HCPCS E0764) to stimulate muscles/nerve groups enabling walking in select SCI patients meeting specific criteria.
    Example deviceParastep I System: battery‑powered transcutaneous FES with walker controls; requires at least 32 training sessions for coverage.
    Coverage noteFES for ambulation is covered only when all listed medical necessity criteria are met (intact LMN, ability to transfer/stand, training completion, no contraindications).
    ASIA Impairment Scale — definition and classification
    DefinitionASIA Impairment Scale: classification of extent of spinal cord injury from A (complete, no S4‑S5 function) through E (normal motor and sensory function).
    UseUsed to describe neurological level and completeness of SCI relevant to candidacy for FES and other interventions.
    CategoriesA (complete), B–D (incomplete variants), E (normal) — used in selection/clinical descriptions.
    Functional Electrical Stimulation (FES) — general definition
    General definitionFunctional Electrical Stimulation (FES): use of electrical impulses to activate paralyzed or weak muscles in precise sequence to produce functional activities such as standing or ambulation.
    Delivery modesTypically transcutaneous surface stimulation or implanted electrode systems depending on indication and device.
    Clinical usesUsed for ambulation (Parastep), diaphragm pacing, spasticity control, and investigational upper extremity neuroprostheses.
    Neuromuscular Electrical Stimulation (NMES) — general definition
    DefinitionNeuromuscular Electrical Stimulation (NMES): electrical stimulation of muscles to treat muscle atrophy or enhance functional activity in neurologically impaired individuals; includes external and implantable systems.
    IndicationsUsed for disuse atrophy, postoperative knee rehab, COPD muscle conditioning, and other studied indications (coverage contingent on criteria).
    Daily use limitPolicy notes recommended protocols and considers >2 hours/day as not medically necessary.
    Diaphragmatic pacing / DPS — definition and implantation概念
    DefinitionDiaphragmatic pacing / Diaphragm pacing stimulation (DPS): implanted electrodes on phrenic nerves or diaphragm motor points connected to an implanted stimulator and external transmitter to condition and stimulate the diaphragm for ventilatory support.
    Implantation conceptLaparoscopic motor‑point mapping with intra‑muscular electrode implantation is described in clinical series; stimulation conditions diaphragm over conditioning period.
    Clinical goalUsed for ventilator‑dependent SCI, central alveolar hypoventilation, and select ALS patients to reduce or replace mechanical ventilation.
    Neuroprosthesis — example devices (NESS H200 / Handmaster)
    DefinitionNeuroprosthesis: a device combining a custom‑fitted orthosis and control unit applying surface electrical stimulation to produce functional movements (example: NESS H200/Handmaster).
    Typical useUsed for upper extremity rehabilitation and home‑based training programs; evidence varies and many indications remain investigational.
    Device componentsCustom orthosis + control unit with adjustable stimulation intensity and training modes.
    Neurogenic bladder (Lapides Classification) — definition
    DefinitionNeurogenic bladder (Lapides Classification): neuropathic voiding dysfunction due to central or peripheral innervation lesions; classified into five categories.
    Clinical relevanceClassification used to guide management and device candidacy (e.g., sacral anterior root stimulator selection).
    Categories listedSensory neurogenic bladder; motor paralytic bladder; uninhibited; reflex neurogenic bladder; autonomous neurogenic bladder.
    Lapides Classification — 5-category scheme for neuropathic voiding dysfunction
    DefinitionLapides Classification: five‑category scheme for neuropathic voiding dysfunction frequently used by urologists.
    ApplicationInforms selection for interventions like Vocare/Finetech‑Brindley sacral anterior root stimulation.
    CategoriesSensory, motor paralytic, uninhibited, reflex, autonomous neurogenic bladder.
    Foot-drop stimulator (FDS) — definition
    DefinitionFoot‑drop stimulator (FDS): external electrical stimulation device that delivers peroneal/common peroneal nerve stimulation to promote ankle dorsiflexion during swing phase to improve gait.
    ExamplesDevices include NESS L300, WalkAide, Odstock ODFS and implanted peroneal stimulators; evidence shows orthotic benefit with mixed therapeutic effects.
    Clinical roleMay provide orthotic benefit during use; comparative trials versus AFOs show mixed results.
    FES-cycling — definition
    DefinitionFES‑cycling: use of electrical stimulation to activate lower‑limb muscles in a cycling motion as an exercise training modality for persons with mobility impairment.
    Typical regimenSessions reported ~30 minutes, 2–3 times per week in MS studies; evidence limited but promising for physiological and mobility outcomes.
    Target populationApplied to persons with moderate‑to‑severe MS and other mobility‑impaired populations in small trials.
    Threshold Electrical Stimulation (TES) — definition
    DefinitionThreshold Electrical Stimulation (TES): low‑intensity electrical stimulation, usually at night, intended to strengthen muscles weakened by non‑use and increase joint mobility.
    Pediatric findingsRCTs in children with spastic diplegic CP found no significant objective motor or ambulatory benefit on blinded measures.
    Clinical noteEvidence does not support routine TES for motor/ambulatory improvement in CP per cited trials.
    Phrenic Nerve Stimulation (PNS) — definition
    DefinitionPhrenic Nerve Stimulation (PNS): transvenous unilateral stimulation of the phrenic nerve to contract the diaphragm for treatment of central sleep apnea or ventilator‑dependent respiratory failure.
    Device exampleRemede System is an implantable PNS system delivering transvenous phrenic nerve stimulation for moderate‑to‑severe CSA.
    Trial contextRCTs required AHI thresholds (e.g., >=20) and medical stability for enrollment; PNS reduced AHI substantially in trials.
    Remede System — implantable phrenic nerve stimulation system definition
    DefinitionRemede System: implantable phrenic nerve stimulation system with subcutaneous battery pack and transvenous leads that monitor respiratory signals and stimulate the phrenic nerve to restore breathing in adults with moderate‑to‑severe central sleep apnea.
    FDA statusFDA approved Oct 6, 2017 for adults with moderate‑to‑severe CSA; not intended for obstructive sleep apnea.
    ContraindicationsShould not be used in patients with active infection or who require MRI.
    EMG-triggered NMES (Care ETS) — definition
    DefinitionEMG‑triggered NMES (Care ETS): an NMES device that detects weak endogenous EMG signals and augments them with stimulation to induce muscle contraction for retraining.
    Proposed usesUsed for retraining, preventing disuse atrophy, and relaxation of muscle spasms per manufacturer/description.
    Evidence noteDevice cited among various NMES devices in background; clinical effectiveness varies by indication.
    Cala Trio / TAPS — device definition
    DefinitionCala Trio / TAPS: a wrist‑worn, non‑invasive peripheral nerve stimulation device that delivers patterned electrical stimulation to median and radial nerves at the patient's tremor frequency; FDA‑cleared for essential tremor.
    ComponentsRechargeable stimulator + base station and wrist connector with on‑board tremor‑frequency calibration.
    Clinical evidenceRCTs and open‑label studies report tremor and ADL improvements up to 3 months; evidence graded low and longer‑term benefit uncertain.
    TAPS — transcutaneous afferent patterned stimulation definition
    DefinitionTAPS (transcutaneous afferent patterned stimulation): non‑invasive wrist‑worn therapy delivering alternating stimulation to median and radial sensory afferents at the patient's tremor frequency to reduce hand tremor.
    MechanismModulates peripheral sensory afferents to influence central tremor networks (VIM) and reduce action/postural tremor.
    Clinical considerationsSafe and generally well tolerated; evidence inconsistent and longer‑term efficacy uncertain.
    Tremor power (accelerometry) — definition
    DefinitionTremor power (accelerometry): objective measure of tremor magnitude recorded by a wrist accelerometer on the device, correlated with clinical rating scales and used as an outcome measure.
    Use in studiesDevice‑recorded accelerometry used for baseline and follow‑up tremor assessment in Cala/TAPS studies and post‑market analyses.
    Supporting documentationDevice logs and accelerometry metrics recommended as supporting documentation for home‑use coverage.
    geko devices (OnPulse) — wearable NMES device definition
    Definitiongeko devices (OnPulse): low‑frequency (1‑Hz) wearable NMES devices that stimulate the common peroneal nerve to activate calf and foot muscle pumps; available as geko T‑3 and W‑3.
    OperationWorn below the knee; adhesive‑embedded electrode device delivering stimulation and discarded after use (single‑use consumable).
    IndicationsIndicated for increasing local blood circulation, reducing edema, preventing venous thrombosis, and supporting wound/tissue healing.
    PoNS / TLNS — definition of trans-lingual neurostimulation
    DefinitionPoNS / TLNS (trans‑lingual neurostimulation): non‑invasive stimulation of facial and trigeminal nerve inputs via the tongue (PoNS device) to promote neuroplasticity when paired with rehabilitation for balance/gait deficits.
    Clinical useUsed adjunctively with intensive PT; trial eligibility included patients plateaued on conventional PT with baseline objective balance deficits.
    Study limitationsEvidence from small trials suggests potential benefit; larger studies needed.
    NMES — general definition for metabolic and functional outcomes
    DefinitionNMES: neuromuscular electrical stimulation to induce muscle contraction, investigated for metabolic and functional outcomes including glycemic control and rehabilitation.
    ApplicationsStudied for disuse atrophy, glycemic control, COPD muscle conditioning, postoperative rehab, and intermittent claudication among others.
    Evidence noteEvidence quality varies by indication; meta‑analyses and RCTs cited for some uses but standardization lacking.
    TOMAC — definition of tonic motor activation device
    DefinitionTOMAC (Tonic Motor Activation): a bilateral peroneal nerve stimulation device delivering high‑frequency stimulation via external units worn below the knee; sessions typically 30 minutes and up to 120 minutes/day.
    IndicationStudied and FDA‑marketed for medication‑refractory moderate‑to‑severe RLS (RESTFUL trial).
    Typical session parameters30‑minute sessions; up to 120 minutes per day (e.g., multiple sessions).
    Walkasins — lower-limb sensory prosthesis definition
    DefinitionWalkasins: a lower‑limb sensory prosthesis with a receptor sole and ankle monitor that senses plantar contact and transmits directional tactile cues to the lower leg to improve balance in peripheral neuropathy patients.
    Candidacy criteriaUsed in patients with impaired plantar sensation, gait/balance problems, FGA <23, and ability to sense tactile stimuli above the ankle (trial criteria).
    Outcome measuresStudies measured FGA, gait speed, TUG, and falls in home‑use trials up to 10–26 weeks.
    Peripheral neuromodulation (wearable) — definition
    DefinitionPeripheral neuromodulation (wearable): wearable technologies that modulate peripheral sensory or motor pathways using non‑invasive stimulation techniques (sensory substitution, augmentation, motor stimulation).
    Implementation categoriesIncludes sensory substitution, sensory augmentation (open/closed loop), and motor stimulation devices for gait, balance, foot‑drop, and postural control.
    Evidence noteEvidence is heterogeneous; many devices are investigational or have limited long‑term data.

    Background and Clinical Evidence Summary

    The policy provides an overview of mechanisms and categories of FES and NMES devices, noting that these systems deliver electrical stimulation to elicit muscle contraction for functional activities (FES) or to treat disuse atrophy (NMES). Representative device types described include transcutaneous FES for ambulation (Parastep I), garment‑integrated NMES, implantable diaphragmatic/phrenic pacing systems, peripheral stimulators (peroneal/foot‑drop devices), and wearable neuromodulation technologies.

    The policy’s evidence commentaries repeatedly emphasize limitations: heterogeneity of trials, small sample sizes, short follow‑up, and insufficient high‑quality randomized data to demonstrate long‑term functional effectiveness for many indications (for example, FES after stroke). These limitations are cited as the reason further robust research is needed and as the basis for investigational or not‑medically‑necessary positions in several indication areas.

    Policy Revision History

    2004-02-06policy_effective

    Policy 0677 became effective.

    2017-10-06device_approval_update

    FDA approved the Remede System for treatment of moderate-to-severe central sleep apnea.

    2023-04device_marketing

    TOMAC (tonic motor activation) system received FDA marketing approval (April 2023) for treatment of medication-refractory restless legs syndrome.

    2026-07-30policy_reviewLatest

    Clinical Policy Bulletin 0677 last reviewed and updated.